Pipeline Partnerships Rubius is advancing two RBC-based candidates, RTX-240 and RTX-224, in Phase 1/2 for solid tumors, with combination strategies and tumor types including NSCLC and RCC. This creates potential sales opportunities for co-development, licensing, or acquisition of rights, as well as partnerships to provide clinical supply and strategic expertise for oncology programs leveraging the RED PLATFORM.

Platform Licensing The RED PLATFORM represents a proprietary technology for engineering and culturing Red Cell Therapeutics. External partners could license the platform to develop additional RBC-based therapies, enabling faster entry into oncology or autoimmune indications without building in-house capability.

Manufacturing Access Rubius’ asset base and infrastructure investments hint at potential contract manufacturing or technology transfer opportunities for RBC therapies. BD play: explore manufacturing collaborations or space-sharing for GMP-grade production of RTX-240/224 or future candidates.

Funding & Incentives A solid funding runway and prior government incentives underscore Rubius’s financial resilience, enabling longer, milestone-driven deals. This can support co-development funding, upfront licensing fees, and shared-investment in clinical or scale-up activities.

Ecosystem Partnerships Past collaborations with entertainment brands highlight an openness to cross-industry partnerships. This could translate into patient recruitment, digital health engagement, or co-branding initiatives to accelerate trial enrollment and patient access strategies.